Reset Pharma
Also known as: Reset Pharmaceuticals
Reset Pharma is a US clinical-stage biotechnology company developing psilocybin-based treatments for patients with life-altering diseases. Its lead candidate RSTP1000 (oral psilocybin) targets demoralization syndrome in cancer patients — a condition with no approved treatments. In November 2023 the company received FDA IND clearance to initiate a Phase 2b multicenter, randomized, dose-ranging trial. The company holds an exclusive worldwide licence from NYU Langone Health and licenses drug supply from Filament Health Corp. Reset has raised $11.1M led by Merida Capital Partners.
Drug Pipeline
1RSTP1000
PsilocybinPhase 2b multicenter randomized dose-ranging trial for demoralization syndrome in cancer patients; FDA IND cleared Nov 2023. Drug in-licensed from Filament Health; IP licensed from NYU Langone.
Quick Facts
- Type
- Private Biotech
- Founded
- 2020
- Lead Stage
- Phase II
- Website
- Visit